Celldex Therapeutics (CLDX) SVP Heath-Chiozzi Buys 95,000 Shares

Margo Heath-Chiozzi, the Senior Vice President of Regulatory Affairs at Celldex Therapeutics, Inc. (NasdaqCM: CLDX), made a notable purchase of 95,000 shares of the company's stock on June 25, 2026. This transaction was not part of a pre-planned trading program and reflects a significant acquisition by an insider.

Insider Buying and Selling at Celldex Therapeutics, Inc.

Margo Heath-Chiozzi wasn't the only insider making moves at Celldex. On the same day, several other executives also purchased shares. Samuel Bates, the SVP and CFO, bought 93,000 shares, while Sarah Cavanaugh, the SVP of Corporate Affairs and Administration, acquired 95,000 shares. Ronald Pepin, the Sr. VP & CBO, Denice Torres, and Neil Garry Arthur each purchased 26,000 shares, signaling strong insider interest in the company's future.

Other Institutional Activity in Celldex Therapeutics

Institutional investors have also been active in Celldex. Wellington Management Group LLP increased its stake by 480,868 shares, bringing its total to over 8.56 million shares worth approximately $271.54 million, marking a 6.0% increase. Meanwhile, Point72 Asset Management, L.P. significantly boosted its holdings by 1,471,582 shares, an 83.7% increase, totaling about 3.23 million shares valued at $102.45 million. On the flip side, FMR LLC reduced its position by 1,158,421 shares, a 23.6% decrease, leaving it with approximately 3.75 million shares valued at $118.92 million.

Celldex Therapeutics, Inc. Stock Down 2.1%

On Tuesday, Celldex Therapeutics' stock was trading at $35.26. The company has a market capitalization of approximately $2.77 billion and a beta of 0.93, indicating moderate volatility compared to the market. The 52-week range for the stock is between $19.52 and $35.79. The company's 50-day moving average stands at $32.10, while the 200-day moving average is $28.27. Celldex has a strong liquidity position with a current ratio of 8.92 and a quick ratio of 8.78, alongside a manageable debt-to-equity ratio of 0.42.

Analysts Set New Price Targets

Analysts have been optimistic about Celldex's prospects. On June 15, 2026, HC Wainwright & Co. reiterated a buy rating with a $42.00 price target. UBS maintained its buy rating with a $45.00 target on June 10, 2026. Wells Fargo also maintained a buy rating, setting a price target of $54.00 as of May 13, 2026. The consensus among analysts is a strong buy, with an average price target of $57.53, based on 15 analyst opinions.

About Celldex Therapeutics

Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey, focusing on developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. With Mr. Anthony S. Marucci as CEO, the company employs 198 people. Celldex is working on monoclonal and bispecific antibodies targeting mast cell mediated diseases, including Barzolvolimab (CDX-0159) for treating chronic urticarias and CDX-622 for inflammatory diseases.

Bottom Line

The recent insider buying activity by Margo Heath-Chiozzi and other executives at Celldex Therapeutics suggests confidence in the company's direction. While insider transactions can offer insights, investors should remember that these reports reflect past actions and may not indicate future performance. Celldex's stock is closely watched, with institutional investors and analysts showing keen interest in its potential growth.